Jan Pander

483 total citations
11 papers, 278 citations indexed

About

Jan Pander is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jan Pander has authored 11 papers receiving a total of 278 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jan Pander's work include Colorectal Cancer Treatments and Studies (5 papers), HER2/EGFR in Cancer Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Jan Pander is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), HER2/EGFR in Cancer Research (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Jan Pander collaborates with scholars based in Netherlands and Taiwan. Jan Pander's co-authors include Henk‐Jan Guchelaar, Hans Gelderblom, Tahar van der Straaten, Cornelis J.A. Punt, Sjoerd H. van der Burg, Ekaterina S. Jordanova, Moniek Heusinkveld, Renée Baak-Pablo, Thorbald van Hall and Hans Morreau and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Clinical Cancer Research.

In The Last Decade

Jan Pander

10 papers receiving 275 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jan Pander Netherlands	9	169	91	68	58	42	11	278
Maddalena Centanni Sweden	5	225 1.3×	46 0.5×	71 1.0×	59 1.0×	24 0.6×	13	311
Carolina Ortiz Spain	9	218 1.3×	158 1.7×	58 0.9×	74 1.3×	88 2.1×	27	433
Lihou Dong China	9	163 1.0×	86 0.9×	51 0.8×	56 1.0×	34 0.8×	19	294
Wenke Wang China	8	59 0.3×	71 0.8×	115 1.7×	27 0.5×	29 0.7×	9	326
William Leslie United States	7	208 1.2×	38 0.4×	47 0.7×	98 1.7×	54 1.3×	17	314
Shaolong Sun China	10	132 0.8×	155 1.7×	41 0.6×	56 1.0×	48 1.1×	21	331
W. Zhang United States	10	153 0.9×	165 1.8×	41 0.6×	62 1.1×	68 1.6×	18	359
Amy Barone United States	9	217 1.3×	102 1.1×	92 1.4×	87 1.5×	61 1.5×	14	396
Alberta Leon Italy	6	160 0.9×	154 1.7×	18 0.3×	47 0.8×	42 1.0×	7	286
Antonino Cassata Italy	9	220 1.3×	47 0.5×	25 0.4×	54 0.9×	35 0.8×	21	292

Countries citing papers authored by Jan Pander

Since Specialization

Citations

This map shows the geographic impact of Jan Pander's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jan Pander with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jan Pander more than expected).

Fields of papers citing papers by Jan Pander

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jan Pander. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jan Pander. The network helps show where Jan Pander may publish in the future.

Co-authorship network of co-authors of Jan Pander

This figure shows the co-authorship network connecting the top 25 collaborators of Jan Pander. A scholar is included among the top collaborators of Jan Pander based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jan Pander. Jan Pander is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Vervloet, Marc, et al.. (2023). Prevalence of chronic kidney disease in the Netherlands and its cardiovascular and renal complications. BMC Nephrology. 24(1). 337–337. 2 indexed citations

Pander, Jan, Stefan Böhringer, Tahar van der Straaten, et al.. (2015). Genome Wide Association Study for Predictors of Progression Free Survival in Patients on Capecitabine, Oxaliplatin, Bevacizumab and Cetuximab in First-Line Therapy of Metastatic Colorectal Cancer. PLoS ONE. 10(7). e0131091–e0131091. 10 indexed citations

Pander, Jan, Moniek Heusinkveld, Tahar van der Straaten, et al.. (2011). Activation of Tumor-Promoting Type 2 Macrophages by EGFR-Targeting Antibody Cetuximab. Clinical Cancer Research. 17(17). 5668–5673. 87 indexed citations

Guchelaar, Henk‐Jan, Jan Pander, Stefan Böhringer, et al.. (2011). Genome-wide association study (GWAS) of the efficacy of capecitabine, oxaliplatin, and bevacizumab in metastatic colorectal cancer in the CAIRO2 trial of the Dutch Colorectal Cancer Group (DCCG).. Journal of Clinical Oncology. 29(15_suppl). 3609–3609.

Pander, Jan, Hans Gelderblom, Ninja Antonini, et al.. (2010). Correlation of FCGR3A and EGFR germline polymorphisms with the efficacy of cetuximab in KRAS wild-type metastatic colorectal cancer. European Journal of Cancer. 46(10). 1829–1834. 63 indexed citations

Pander, Jan, Judith A.M. Wessels, Hans Gelderblom, et al.. (2010). Pharmacogenetic interaction analysis for the efficacy of systemic treatment in metastatic colorectal cancer. Annals of Oncology. 22(5). 1147–1153. 31 indexed citations

Pander, Jan, Henk‐Jan Guchelaar, & Hans Gelderblom. (2010). Pharmacogenetics of small-molecule tyrosine kinase inhibitors: Optimizing the magic bullet.. PubMed. 12(6). 654–61. 8 indexed citations

Pander, Jan, Judith A.M. Wessels, Ron H.J. Mathijssen, Hans Gelderblom, & Henk‐Jan Guchelaar. (2010). Pharmacogenetics of Tomorrow: The 1 + 1 = 3 Principle. Pharmacogenomics. 11(7). 1011–1017. 13 indexed citations

Nieuwkoop, Cees van, J. W. van’t Wout, Willem JJ Assendelft, et al.. (2009). Treatment duration of febrile urinary tract infection (FUTIRST trial): a randomized placebo-controlled multicenter trial comparing short (7 days) antibiotic treatment with conventional treatment (14 days). BMC Infectious Diseases. 9(1). 131–131. 12 indexed citations

10.

Pander, Jan, Hans Gelderblom, & Henk‐Jan Guchelaar. (2007). Pharmacogenetics of EGFR and VEGF inhibition. Drug Discovery Today. 12(23-24). 1054–1060. 40 indexed citations

11.

Pander, Jan, Hans Gelderblom, & Henk‐Jan Guchelaar. (2007). Insights into the role of heritable genetic variation in the pharmacokinetics and pharmacodynamics of anticancer drugs. Expert Opinion on Pharmacotherapy. 8(9). 1197–1210. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact